MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
November 15, 2017 08:00 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, Fla., Nov. 15, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
MEDITE Cancer Diagnostics Reports 2017 Third Quarter Financial Results
November 14, 2017 17:25 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, Fla., Nov. 14, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
November 08, 2017 08:31 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, Fla., Nov. 08, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
MEDITE Cancer Diagnostics Reports Closing of $5.4 Million Private Financing, Providing Working Capital to Drive Commercial Plan Execution
October 03, 2017 07:05 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, Fla., Oct. 03, 2017 (GLOBE NEWSWIRE) -- MEDITE Cancer Diagnostics, Inc. (OTCQB:MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers...
MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results
August 14, 2017 17:00 ET
|
MEDITE Cancer Diagnostics
ORLANDO, FL--(Marketwired - Aug 14, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company"), specializing in the development, manufacturing and marketing of molecular biomarkers and...
MEDITE Cancer Diagnostics to Launch SureCyte(TM) C1 Stain Globally at the 29th European Congress of Pathology
July 27, 2017 08:00 ET
|
MEDITE Cancer Diagnostics
ORLANDO, FL--(Marketwired - Jul 27, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical...
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
May 10, 2017 09:01 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, FL--(Marketwired - May 10, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and...
MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
April 28, 2017 09:01 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, FL--(Marketwired - Apr 28, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company") specializing in the development, manufacturing and marketing of molecular biomarkers and...
MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer
April 27, 2017 16:01 ET
|
MEDITE Cancer Diagnostics, Inc.
ORLANDO, FL--(Marketwired - Apr 27, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) (the "Company"), specializing in the development, manufacturing, and marketing of molecular biomarkers and...
MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors
March 07, 2017 09:29 ET
|
MEDITE Cancer Diagnostics
ORLANDO, FL--(Marketwired - Mar 7, 2017) - MEDITE Cancer Diagnostics, Inc. (OTCQB: MDIT) ("MEDITE" or the "Company"), a medical technology company specializing in the development, engineering,...